BioVie Inc. investors adequately pleaded securities fraud claims over statements about the progress of a clinical trial for ...

reflecting the anticipated value of future cash flows from BioVie’s leading drug candidate, Bezisterim (NE3107). Bezisterim is currently under investigation for treating Early Parkinson’s Disease, ...

An experimental drug appears to reduce the risk of Alzheimer’s in people “destined” to develop the disease in middle age. For 22 patients who had no cognitive problems at the start of the ...

Early-onset Alzheimer’s disease progresses more rapidly and often strikes people in the prime of their lives. Treatment options remain limited. But new data from a recent clinical trial suggests that ...

For people who discover they carry genetic mutations that virtually guarantee they will develop Alzheimer’s disease ... the experimental anti-amyloid drug for an average of eight years, with ...

An experimental drug that clears amyloid beta from the brain cut the risk of developing Alzheimer’s by 50% among a group of 22 people with genetic mutations that all but guarantee they would ...

Published in the Lancet Neurology journal, a new study found increased doses and long-term use of the drug could delay the onset of Alzheimer's symptoms for those with a genetic form of the disease.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The EU’s medicines regulator has declined to approve Eli Lilly’s new Alzheimer’s drug, deciding the ...

BioVie Inc. (NASDAQ ... Long-COVID, and Alzheimer’s Disease, with potential applications in longevity therapeutics. The drug targets neuroinflammation in Parkinson’s Disease patients and ...